The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fast Track, 2002Comparitive gene expression analysis of the brain in Parkinson's Disease and in familial encephalopathy with neuroserpin inclusion bodies (FENIB): implications for pathogenesis
Parkinson's disease (PD) is a common neurological disorder that affects the control of movement and frequently cognition. Examination of postmortem brain tissue from subjects with Parkinson's disease...
-
Fast Track, 2002Further evaluation fo the neuroprotective effects of citrus flavenoid tangeretin in a pre-clinical model of PD
Previously, Dr. Dexter's team has demonstrated that neurodegeneration in Parkinson's disease (PD) is associated with a process called oxidative stress. Oxidative stress is caused by either an increase...
-
Fast Track, 2002Dyskinesia & Abnormal Regulation of DARPP-32
L-DOPA-induced dyskinesia (abnormal involuntary movements, AIMs) is a major complication of the pharmacotherapy of Parkinson's disease. Subjects suffering from L-DOPA-induced dyskinesia show complex...
-
Fast Track, 2002Prevention and Treatment of Parkinson’s Disease Pathology in a-Synuclein Transgenic Mice
The hallmark lesions in the brains of patients with Parkinson's disease (termed Lewy bodies) are mainly composed of a-synuclein. This small protein normally regulates proper communication between...
-
Fast Track, 2002Dynamical interactions between basal ganglia structures and cerebral Cortex: an in Vivo Multi-site Recording Study
Recent successful strategies in treating Parkinson's disease consist of placing selective lesions in globus pallidus or stimulating in subthalamic nucleus (deep brain stimulation). Yet the dynamical...
-
Community Fast Track, 2002VDA Agonist Neuroprotection via AKT Pathway in MPTP Pre-clinical Model of Parkinson's
Antiparkinsonian agents that are direct dopamine (DA) agonists, such pramipexole, have shown to be neuroprotective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage to the DA...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.